Powered by: Motilal Oswal
01-01-1970 12:00 AM | Source: Accord Fintech
Ami Organics gains on getting nod for capital expenditure plan for Ankleshwar Unit
News By Tags | #6898 #1660 #572

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel

AMI Organics is currently trading at Rs. 1146.80, up by 20.80 points or 1.85% from its previous closing of Rs. 1126.00 on the BSE.

The scrip opened at Rs. 1158.00 and has touched a high and low of Rs. 1165.00 and Rs. 1121.00 respectively. So far 26477 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1438.50 on 22-Sep-2021 and a 52 week low of Rs. 764.15 on 24-Feb-2022.

Last one week high and low of the scrip stood at Rs. 1165.00 and Rs. 1010.00 respectively. The current market cap of the company is Rs. 4190.26 crore.

The promoters holding in the company stood at 41.05%, while Institutions and Non-Institutions held 7.86% and 51.08% respectively.

Ami Organics’ board has approved the capital expenditure (Capex) Plan for Ankleshwar Unit. The Capex plan of Ankleshwar Unit entails an outlay of Rs 190 crore to build a brownfield plant to support the future business growth of the company’s advanced pharmaceutical intermediates segment. The existing structure of Ankleshwar Unit will be completely demolished and a new Plant will be built on the land.

The Ankleshwar unit has received necessary environmental clearance and the new facility will have around 90 reactors taking the total reactor capacity to 436KL. The plant is expected to start commercial operations from January 2024. The Capex will be funded through a mix of General Corporate funds of IPO proceeds, internal accruals, and bank finance. The Board of Directors of Company has finalised and approved the Capex Plan for Ankleshwar Unit at its meeting held on April 28, 2022.

The company manufactures specialty chemicals that are used towards the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients (APIs) and New Chemical Entities (NCE), and key starting material for agrochemical and fine chemicals.